[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-covid-19-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-covid-19-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,49,82,108,134,169,193,218,237,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100634885","physical-functions-and-lifestyle-behaviours-in-post-covid-19-syndrome-based-on-circadian-rhythms-100634885",false,"NCT07545499","Physical Functions and Lifestyle Behaviours in Post-COVID-19 Syndrome Based on Circadian Rhythms","Comparison of Respiratory Muscle Strength, Physical Activity Level, and Dietary Habits in Individuals With Post-COVID-19 Syndrome Having Different Circadian Rhythms","Inclusion Criteria:\n\n* Diagnosed with Post-COVID-19 Syndrome\n* Aged between 18-65 years\n* Able to read and understand Turkish\n* Voluntary participation\n* Classified as Post-Covid Functional Status Scale (PCFS) grade 2-3\n* Clinically stable condition\n* No uncontrolled comorbidities (e.g., hypertension, diabetes under control)\n* No orthopedic or neurological conditions affecting exercise testing\n\nExclusion Criteria:\n\n* Recent myocardial infarction or pulmonary embolism\n* Severe uncontrolled chronic diseases\n* Neurological or orthopedic conditions limiting mobility\n* Psychiatric or neurological disorders affecting cooperation or test compliance\n* Inability to complete assessments","ALL","18 Years","65 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","Post-COVID-19 syndrome is associated with persistent symptoms such as fatigue, reduced physical activity, and impaired respiratory function. Circadian rhythm differences (chronotype) may influence lifestyle behaviors including physical activity, nutrition, and sleep patterns.\n\nThis observational cross-sectional study aims to compare respiratory muscle strength, physical activity levels, and nutritional habits among individuals with post-COVID-19 syndrome according to their chronotype (morning, intermediate, and evening types).\n\nAdditionally, genetic analysis of the CLOCK gene polymorphism will be performed to support objective evaluation of circadian rhythm differences. The findings of this study may help to better understand the role of circadian rhythm in post-COVID-19 syndrome and contribute to the development of individualized rehabilitation and lifestyle interventions.",[25],"Post-COVID-19 Syndrome",[27,28,29,30,31,32,33,34,35],"Circadian Rhythm","Chronotype","Respiratory Muscle Strength","Physical Activity","Nutrition","Post-COVID","Long COVID","CLOCK Gene","Genetic Polymorphism","RECRUITING","2026-04-21",{"date":39,"type":40},"2026-04-22","ACTUAL",{"date":42,"type":40},"2025-05-22",{"date":44,"type":21},"2027-05-22",{"name":46,"class":47},"Hacettepe University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":48},"100522430","improving-post-covid-19-syndrome-with-hyperbaric-oxygen-treatments-100522430","NCT06082518","Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments","Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments (PCS-HBOT Study)","PCS-HBOT","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Officially diagnosed with post COVID-19 condition by a healthcare practitioner\n3. At least three months since SARS-CoV-2 infection\n4. Symptoms that persist more than 12 weeks:\n\n   * Chronic fatigue (must include) along with one of the following symptoms:\n   * Difficulty thinking or problem solving ('brain fog')\n   * Stress or anxiety\n\nExclusion Criteria:\n\n1. Contraindications\u002Fmedically unfit to receive hyperbaric treatments at an outpatient facility (pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)\n2. Patients with cognitive difficulties and\u002For mental retardation before COVID diagnosis\n3. History of traumatic brain injury\n4. Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)\n5. Known pregnancy or planning a pregnancy in women of childbearing age",{"count":58,"type":21},40,"INTERVENTIONAL",[61],"NA","Over 500 million people have been infected with COVID-19, and to date, more than 6 million people have died. Many individuals who have recovered from COVID-19 continue to experience symptoms even after they have been \"cured\" of the disease. This condition is known as post COVID-19 condition, which can have serious health consequences. A common symptom among these individuals is chronic fatigue, characterized by persistent tiredness or lack of energy. This study aims to explore a novel treatment for symptoms of post COVID-19 condition, known as hyperbaric oxygen therapy. This approach has shown promise in helping people with post COVID-19 conditions and treating some other causes of fatigue.\n\nHyperbaric oxygen therapy involves placing patients in a small chamber where they receive high oxygen gas levels. However, this treatment is expensive and time-consuming, and it is unclear if this treatment can be effectively assessed in a large-scale research study. This small study will help us decide if conducting a large research study is feasible. The investigators aim to assess if hyperbaric oxygen therapy can improve symptoms of post COVID-19 condition, such as fatigue.",[64,25,65,66,67,68],"Post COVID-19 Condition","Post-COVID Syndrome","COVID-19","Fatigue","Fatigue Syndrome, Chronic",[70,71,64,67,72,66],"Hyperbaric Oxygen Therapy","HBOT","Severe Acute Respiratory Syndrome-CoV-2","2026-03-12",{"date":75,"type":40},"2026-03-16",{"date":77,"type":40},"2024-01-02",{"date":79,"type":21},"2027-05",{"name":81,"class":47},"Sunnybrook Health Sciences Centre",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":89,"targetDuration":4,"studyType":59,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":48},"100596936","effectiveness-of-functional-respiratory-muscle-training-in-post-covid-19-syndrome-100596936","NCT07051954","Effectiveness of Functional Respiratory Muscle Training in Post-COVID-19 Syndrome","Investigation of the Effects of Functional Respiratory Muscle Training on Respiratory Muscle Function, Exercise Capacity, Skeletal Muscle Strength, and Muscle Endurance in Individuals With Post-COVID-19 Syndrome","Inclusion Criteria:\n\n* Diagnosed with Post-COVID-19 Syndrome.\n* Literate and able to understand study procedures.\n* Aged between 18 and 65 years.\n* Willing to voluntarily participate in the study.\n* Classified as functional class 2-3 according to the Post-COVID-19 Functional Status Scale (PCFS).\n* Clinically stable; comorbid conditions such as hypertension or diabetes must be controlled.\n* No orthopedic or neurological conditions that would prevent assessment of peripheral muscle strength, balance, or exercise capacity.\n\nExclusion Criteria:\n\n* History of recent myocardial infarction or pulmonary embolism.\n* Presence of uncontrolled chronic diseases.\n* Any orthopedic or neurological disorders that limit mobility.\n* Neurological impairments (e.g., cerebrovascular disease) or psychiatric disorders that impair cooperation or compliance with exercise testing.",{"count":58,"type":21},[61],"This study aims to investigate the effects of core stabilization exercises and functional inspiratory muscle training (IMT) on various physiological and psychological parameters in individuals with post-COVID-19 syndrome. Participants diagnosed with post-COVID-19 syndrome will be randomly assigned to two groups using stratified computer-assisted randomization. One group will undergo an 8-week core stabilization training, while the other will receive combined core stabilization and IMT training. Exercise training will be conducted three times a week, with each session lasting 50 minutes.\n\nComprehensive pre- and post-intervention assessments will be conducted, including exercise capacity, respiratory and peripheral muscle strength, trunk endurance, balance, anxiety, depression, and fatigue levels. The primary outcome measures are respiratory muscle strength and trunk endurance.\n\nParticipants must be aged 18-65 years, have at least a primary education level, speak Turkish, and be classified as level 2-3 on the Post-COVID-19 Functional Status Scale (PCFS). Eligible participants will be referred by the Internal Medicine Department at Hacettepe University.\n\nThe study will utilize various assessment tools, including maximal inspiratory\u002Fexpiratory pressure (MIP\u002FMEP) tests, Functional Movement Screen (FMS), plank and Sorenson endurance tests, the Timed Up and Go Test for balance, handgrip and knee extension strength tests, body composition analysis, and the SF-36 quality of life questionnaire.",[93,94,95],"Post COVID-19 Syndrome","Functional Inspiratory Muscle Training","Core Stabilization",[65,97,98,99,95],"Trunk Muscle Endurance","Exercise Capacity","Functional Inspiratory Muscle Training (IMT)","2026-01-13",{"date":102,"type":40},"2026-01-14",{"date":104,"type":40},"2025-09-15",{"date":106,"type":21},"2026-12-30",{"name":46,"class":47},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":59,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":48},"100529836","transcranial-pulse-stimulation-tps-in-post-covid-19-100529836","NCT06178952","Transcranial Pulse Stimulation (TPS) in Post-COVID-19","Inclusion Criteria:\n\n* Signed written informed consent\n* PCR-confirmed SARS-CoV-2 infection, laboratory confirmed antibody detection for SARS-CoV-2, or physician-verified COVID-19 infection\n* At least 12 months after initial SARS-CoV-2 infection that led to Post-COVID (subsequent SARS-CoV-2 infections are not a reason for exclusion)\n* Diagnosis of Post-COVID Syndrome or independent suspected diagnosis of Post-COVID Syndrome (Considering that physicians generally hesitate to provide clear-cut Post-COVID diagnoses, a tentative diagnosis by an independent general practitioner or a specialist in a field associated with Post-COVID will suffice for entering this study)\n* Age: 20-80\n* Evidence of a negative pregnancy test if medically adequate\n\nExclusion Criteria:\n\n* Clinically relevant realization of pre-COVID diseases with similar symptoms as Post-COVID\n* MoCA score \\\u003C17 (cut-off for dementia)\n* BDI-II score ≥29 (cut-off for severe depression)\n* FIS \\\u003C10 (cut-off for no fatigue)\n* Brain implants\n* Non-MR-compatible metal parts in the body\n* Metal parts in the head\n* Use of anticoagulants\n* Non-MR-compatible claustrophobia\n* Non-MR-compatible pacemaker\n* Pregnant and breastfeeding women\n* Clinically relevant history of surgery on the head, heart, or vessels\n* Relevant corticosteroid treatments administered within 6 weeks prior to the first application\n* Tumor of the head if relevant for treatment\n* Blood clotting disorders\n* Participation in other studies","20 Years","80 Years",{"count":117,"type":21},102,[61],"The objective of the present study is to demonstrate treatment efficacy of transcranial pulse stimulation for patients with Post-COVID-19 related neurological symptoms (fatigue, cognitive deficits, mood deterioration). Fatigue, as measured by the Fatigue Impact Scale (FIS), will represent the primary outcome variable. The verum treatment will be compared to a sham (placebo) condition.",[25,67],[122,123,67,124],"Transcranial Pulse Stimulation","Post-COVID-19","Non-invasive brain stimulation","2025-12-19",{"date":127,"type":40},"2025-12-23",{"date":129,"type":40},"2024-01-08",{"date":131,"type":21},"2027-01",{"name":133,"class":47},"Medical University of Vienna",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":59,"phases":144,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":164,"leadSponsor":166,"locationsCount":48},"100601455","effects-of-kneipp-hydrotherapy-in-post-covid-19-patients-100601455","NCT07110714","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients: A Randomized Controlled Trial","HydroCoVitalB","Inclusion Criteria:\n\n* Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)\n* Barthel-Index \\>80\n* Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability\n* Written informed consent\n\nExclusion Criteria:\n\n* Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)\n* Prior regular practice of Kneipp applications",{"count":143,"type":21},30,[61],"This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.",[64,147,148,93,149],"Post COVID-19 Condition (PCC)","Post COVID-19","Long COVID-19 Syndrome",[151,152,153,154,155,156,157,158,159],"therapy","intervention","hydrotherapy","Kneipp","balneotherapy","quality of life","PCC","long COVID","post COVID-19","2025-12-01",{"date":162,"type":40},"2025-12-02",{"date":160,"type":40},{"date":165,"type":21},"2027-10-31",{"name":167,"class":168},"Eggensberger OHG","INDUSTRY",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":59,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":48},"100528085","pursuing-reduction-in-fatigue-after-covid-19-via-exercise-and-rehabilitation-prefacer-a-randomized-feasibility-trial-100528085","NCT06156176","Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial","PREFACER","Inclusion Criteria:\n\n* Adults of at least 18 years of age\n* Able to provide informed consent\n* Can speak and understand English\n* Documented history of SARS-CoV-2 infection (positive PCR\u002Fantigen test during acute illness or clinical diagnosis by physician during or after the acute illness)\n* Fatigue symptoms within 3 months of COVID-19 infection, lasting at least 2 months\n* Fatigue symptoms cannot be explained by an alternative diagnosis\n* Fatigue symptoms may be new onset following initial recovery from an acute COVID-19 infection or persist from the initial illness\n* Fatigue symptoms may have an episodic nature, fluctuate or relapse over time\n* Minimal functional capability: able to walk 10-15 minutes and be recovered within 30-60 minutes or without significant post-exertional malaise (PEM)\n* Has applicable technology to access Microsoft Teams and Webex (i.e., computer, laptop, tablet)\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\n* Pre-existing physical, cognitive, and\u002For mental health conditions that make exercise contraindicated, consent unattainable, or that cause symptoms similar to those seen in post COVID-19 (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome) that could affect data\n* Inability to follow study procedures\n* Pregnant and\u002For breastfeeding\n* Received investigational agents as part of a separate study within 30 days of the screening visit\n* Has any type of metal bodily implant in head or heart (i.e., pins, plates, pacemakers)\n* Current participation in other studies related to COVID-19, exercise, and\u002For fatigue interventions OR participation within 30 days of the screening visit",{"count":177,"type":21},60,[61],"Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatment group will receive an 8-week multi-modal rehabilitation program with two 50-minute sessions per week. 60 participants will be recruited, randomly assigned to the COVIDEx program or standard of care (SoC) and followed for 24 weeks.",[181,182,25,65,67,64,183],"Long-COVID","Long COVID-19","Post-COVID Condition","2025-07-29",{"date":186,"type":40},"2025-08-01",{"date":188,"type":40},"2025-04-01",{"date":190,"type":21},"2026-04-01",{"name":192,"class":47},"Lawson Research Institute of St. Joseph's",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":201,"targetDuration":4,"studyType":59,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":48},"100507685","yoga-versus-health-education-for-the-treatment-of-persistent-fatigue-in-patients-with-post-covid-19-syndrome-100507685","NCT05890599","Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome","Randomized Multicenter Clinical Trial: Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome","YoFaPoCo","Inclusion Criteria:\n\n* Confirmed COVID-19 diagnosis\n* Follow-up symptoms of ≥ 12 weeks\n* Persistent fatigue (scores ≥4 on the binomial Chalder Fatigue Scale).\n* Self-assessment that fatigue was a consequence of COVID-19 disease\n* Age 18-65 years\n\nExclusion Criteria:\n\n* Chronic medical conditions or regular use of medications associated with fatigue\n* Indication of health cause of fatigue other than post-COVID.\n* Indication of other factors as the main cause of fatigue\n* Physical limitations that do not allow participation in the yoga intervention\n* Pregnancy, breastfeeding\n* Concurrent participation in other clinical trials\n* Current yoga practice",{"count":202,"type":21},100,[61],"Evaluation of the short- and medium-term effect of a yoga intervention in addition to routine care compared to health education in addition to routine care on fatigue in patients with post covid syndrome.",[25,206],"Fatigue Post Viral",[67,208],"Covid","2025-07-04",{"date":211,"type":40},"2025-07-10",{"date":213,"type":40},"2023-06-10",{"date":215,"type":21},"2026-03-31",{"name":217,"class":47},"University Hospital Tuebingen",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":224,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":48},"100489268","retinal-neurovascular-coupling-in-patients-previously-infected-with-covid-19-100489268","NCT05650905","Retinal Neurovascular Coupling in Patients Previously Infected With COVID-19","Inclusion Criteria:\n\nInclusion criteria for healthy subjects\n\n* Men and women aged over 18 years\n* Non-smokers\n* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant\n* No previous history of COVID-19 infection\n* Negative testing for SARS-CoV-2 seroprevalence using nucleocapsid antibody tests\n* Negative PCR test for SARS-CoV-2\n* Normal ophthalmic findings, ametropy \\\u003C 6 Dpt.\n\nInclusion criteria for subjects with history of COVID-19 infection\n\n* Men and women aged over 18 years\n* Non-smokers\n* History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history) within the last 6 months\n* Positive testing for SARS-CoV-2 seroprevalence using spike protein IgG antibody tests\n* Negative PCR test for SARS-CoV-2\n\nInclusion criteria for subjects with long COVID-19\n\n* Men and women aged over 18 years\n* Non-smokers\n* History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history)\n* Positive testing for SARS-CoV-2 seroprevalence\n* Negative PCR test for SARS-CoV-2\n* Long Covid according to the latest WHO-Guidelines\n\nExclusion Criteria:\n\nAny of the following will exclude a healthy control subject from the study:\n\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\n* Presence or history of a severe medical condition as judged by the clinical investigator\n* Participation in a clinical trial in the 3 weeks preceding the study\n* Blood donation during the previous three weeks\n* History or family history of epilepsy\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Best corrected visual acuity \\\u003C 0.8 Snellen\n* Pregnancy, planned pregnancy or lactatin\n* History of epilepsia\n\nAny of the following will exclude a subject with history of COVID-19 infection from the study:\n\n* Blood donation during the previous three weeks\n* History or family history of epilepsy\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Best corrected visual acuity \\\u003C 0.8 Snellen\n* Ametropy \\>6 Dpt\n* Pregnancy, planned pregnancy or lactating\n* History of epilepsia\n\nAny of the following will exclude a subject with long COVID-19 from the study:\n\n* Blood donation during the previous three weeks\n* History or family history of epilepsy\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Best corrected visual acuity \\\u003C 0.8 Snellen\n* Ametropy \\>6 Dpt\n* Pregnancy, planned pregnancy or lactating\n* History of epilepsia\n* Diabetes mellitus",true,{"count":226,"type":21},90,"The Study objective is to measure retinal neurovascular coupling and blood flow parameters in patients previously infected with COVID-19, long COVID-19 and healthy age- and sex- matched control subjects",[66,25],"2025-05-13",{"date":231,"type":40},"2025-05-16",{"date":233,"type":40},"2021-07-26",{"date":235,"type":21},"2025-12-31",{"name":133,"class":47},{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":244,"targetDuration":4,"studyType":59,"phases":246,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":254,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":48},"100555353","transcutaneous-vagus-nerve-stimulation-tvns-for-improved-recovery-after-exertion-100555353","NCT06510985","Transcutaneous Vagus Nerve Stimulation (tVNS) for Improved Recovery After Exertion.","Transcutaneous Vagus Nerve Stimulation (tVNS) for Improved Recovery After Exertion in Patients With Long\u002FPost-COVID.","Inclusion Criteria:\n\n* individuals who have previously tested positive for SARS-CoV-2 infection (preferred PCR-Test) or have a medically confirmed history of COVID-19 (preferred SARS-CoV-2 Antibody-test) and have persistent symptoms (including Post-COVID) .\n* clinical diagnoses made by physician: individuals are included with at least one persistent symptom for at least 4 weeks (Long-COVID) or at least 8 weeks (Post-COVID) following the SARS-CoV-2 infections, such as fatigue, shortness of breath, brain fog, headaches, irritability, cognitive difficulties, muscle or joint pain, sleep disturbances, etc.\n* Participants should not have an alternative explanation for their persistent symptoms, ruling out other medical or psychiatric conditions.\n\nExclusion Criteria:\n\n* lack of capacity for consent\n* insufficient German language skills: Participants must have sufficient (B2 German) language skills to understand the informed consent form, study procedures, and questionnaires.\n* Intensive Care Unit treatment during COVID-19 infection\n* BMI \\> 18.5 \\& BMI \\\u003C 35 kg\u002Fm2\n\nLifetime (according to DSM 5):\n\n* brain injury, stroke, epilepsy, or history of seizures\n* schizophrenia\n* bipolar disorder\n* severe substance use disorders, except tobacco\n* cardiac arrhythmia, coronary heart disease\n* 12-month prevalence: pregnancy or nursing\n\nAdditional exclusion criteria for a safe application of tVNS:\n\n* active implant (pacemaker, cochlear implant, implanted electrode device) and cerebral shunts\n* required permanent use of left-sided hearing aid\n* ear infections, open wounds, or impaired skin at electrode sites",{"count":245,"type":21},120,[61],"Widespread infection with SARS-CoV-2 has resulted in millions of people having Post-COVID. Post-COVID is a complex, non-monolithic disease with diverse clinical manifestations. Symptoms range from fatigue, brain fog, muscle aches and shortness of breath, affecting multiple organ systems simultaneously. To directly address this multi-organ component of Post-COVID, innovative treatment methods are urgently needed. One potential treatment that we will investigate in our study, is the intervention via the vagus nerve, as the cranial nerve plays a central role in communication between the body and the brain and influences targeted behavior. This innovative approach is based on our clinically relevant findings regarding the effects where acute tVNS increased the level of effort (Neuser et al., 2020; Ferstl et al., 2021), specifically targeting a key symptom of Post-COVID. In the proposed study, the investigators aim to investigate the effectiveness of transcutaneous vagus nerve stimulation (tVNS) as a non-invasive, self-administered treatment for Post-COVID symptoms at home. To evaluate the clinically relevant effects of repeated taVNS application (high-intensity stimulation), the investigators will employ a randomized cross-over design to investigate stimulation-induced changes in fatigue, depression and motivation to work for reward compared to low-intensity stimulation and to a control group.",[25],[25,250,251,252,253],"taVNS","effort","fatigue","heart rate","NOT_YET_RECRUITING","2024-07-18",{"date":257,"type":40},"2024-07-19",{"date":257,"type":21},{"date":260,"type":21},"2027-12",{"name":217,"class":47},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":224,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":48},"100496559","cohort-follow-up-of-epidemic-and-neuroimaging-for-patients-during-the-1st-wave-of-the-covid-19-in-china-100496559","NCT05745805","Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China","Inclusion Criteria:\n\nConfirmed diagnosis of mild Covid-19 (WHO criteria)\u002FConfirmed diagnosis of moderate Covid-19 (WHO criteria)\u002FHealthy people who have not had COVID-19\n\nExclusion Criteria:\n\nHistory of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc. Participants with indication for MRI studies",{"count":269,"type":21},600,"Our main objective is to analyze the development of physical impact, mental health and blood profile over follow-up time during the 1st wave of the COVID-19. Besides, we aim to establish a database of post-COVID-19 based on simultaneous cortico-spinal magnetic resonance imaging data to identify high-risk patients with long COVID and prevent the neurological symptoms evolution, optimize the tactics of management in China.",[66,25,272,273],"Acute COVID-19","Post-Acute COVID-19",[66,25,275,276,277],"Neuroimaging","Epidemic","Simultaneous Cortico-Spinal Magnetic Resonance Imaging","2023-02-24",{"date":280,"type":40},"2023-02-27",{"date":282,"type":40},"2023-01-12",{"date":284,"type":21},"2026-09-12",{"name":286,"class":47},"First Affiliated Hospital Xi'an Jiaotong University"]